XML 100 R85.htm IDEA: XBRL DOCUMENT v3.24.2
Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details) - EUR (€)
€ in Millions
 6 Months Ended 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses € (2,010) € (1,422) € (3,516)
Other operating income 617 617 1,292
Other operating income/(expenses), net related to Regeneron (1,745) (1,321) (2,979)
Other related parties | Other operating income (expense)      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 118 160  
Monoclonal Antibodies Alliance      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (1,837) (1,418) (3,196)
Monoclonal Antibodies Alliance | Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (1,934) (1,449) (3,321)
Monoclonal Antibodies Alliance | Additional share of profit paid by Regeneron towards development costs      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 389 291 668
Monoclonal Antibodies Alliance | Reimbursement to Regeneron of selling expenses incurred      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (292) (260) (543)
Other (mainly Zaltrap and Libtayo)      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income and expenses 92 97 217
Regeneron | Other operating income (expense)      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 96 102 € 227
Regeneron | Other related parties | Reimbursement to Regeneron of selling expenses incurred      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses € (1,841) € (1,423)